Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising outcomes in initial human studies. Current examination https://socialaffluent.com/story6977209/retatrutide-emerging-research-and-projected-clinical-uses